| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $149,913 | 1 | 13 |
Sells | $18,319,855 | 7 | 87 |
| Aubuchon Neil William | Chief Commercial Officer | 1 | $149,913 | 0 | $0 | $149,913 |
| FOEHR MATTHEW W | director | 0 | $0 | 1 | $561,694 | $-561,694 |
| Mancini Marianna | Chief Operating Officer | 0 | $0 | 2 | $2.51M | $-2.51M |
| ZANTE GREG | Chief Financial Officer | 0 | $0 | 2 | $2.61M | $-2.61M |
| Lian Brian | President & CEO | 0 | $0 | 2 | $12.64M | $-12.64M |
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's …
Over the last 12 months, insiders at Viking Therapeutics, Inc. have bought $149,913 and sold $18.32M worth of Viking Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viking Therapeutics, Inc. have bought $134,082 and sold $35.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Aubuchon Neil William (Chief Commercial Officer) — $149,913.
The last purchase of 4,475 shares for transaction amount of $149,913 was made by Aubuchon Neil William (Chief Commercial Officer) on 2026‑03‑10.
| 2026-07-29 | Sale | Lian Brian | President & CEO | 148,517 0.1275% | $33.32 | $4.95M | -3.84% | |
| 2026-07-29 | Sale | Mancini Marianna | Chief Operating Officer | 18,217 0.0157% | $33.47 | $609,636 | -3.84% | |
| 2026-07-29 | Sale | ZANTE GREG | Chief Financial Officer | 21,217 0.0183% | $33.47 | $710,141 | -3.84% | |
| 2026-03-10 | Aubuchon Neil William | Chief Commercial Officer | 4,475 0.0039% | $33.50 | $149,913 | -5.51% | ||
| 2026-01-05 | Sale | Lian Brian | President & CEO | 233,409 0.2117% | $32.96 | $7.69M | +0.78% | |
| 2026-01-05 | Sale | Mancini Marianna | Chief Operating Officer | 57,661 0.0523% | $32.98 | $1.9M | +0.78% | |
| 2026-01-05 | Sale | ZANTE GREG | Chief Financial Officer | 57,661 0.0522% | $32.90 | $1.9M | +0.78% | |
| 2026-01-02 | Sale | FOEHR MATTHEW W | director | 16,000 0.0141% | $35.11 | $561,694 | -8.57% | |
| 2025-10-28 | Sale | Lian Brian | President & CEO | 38,989 0.0358% | $35.01 | $1.36M | -4.55% | |
| 2025-10-28 | Sale | Mancini Marianna | Chief Operating Officer | 6,185 0.0057% | $35.00 | $216,492 | -4.55% | |
| 2025-10-28 | Sale | ZANTE GREG | Chief Financial Officer | 6,185 0.0057% | $35.00 | $216,481 | -4.55% | |
| 2025-10-27 | Sale | Rowland Charles A Jr | director | 60,000 0.056% | $35.57 | $2.13M | -7.13% | |
| 2025-07-03 | Sale | Lian Brian | President & CEO | 26,889 0.0237% | $27.80 | $747,633 | +15.73% | |
| 2025-07-03 | Sale | Mancini Marianna | Chief Operating Officer | 4,266 0.0037% | $27.77 | $118,473 | +15.73% | |
| 2025-07-03 | Sale | ZANTE GREG | Chief Financial Officer | 4,266 0.0037% | $27.76 | $118,428 | +15.73% | |
| 2025-03-31 | Rouan Sarah Kathryn | director | 1,240 0.0011% | $24.15 | $29,943 | +30.48% | ||
| 2025-01-06 | Sale | Lian Brian | President & CEO | 194,490 0.1752% | $42.75 | $8.31M | -29.98% | |
| 2025-01-06 | Sale | Mancini Marianna | Chief Operating Officer | 54,215 0.0488% | $42.75 | $2.32M | -29.98% | |
| 2025-01-06 | Sale | ZANTE GREG | Chief Financial Officer | 50,309 0.0453% | $42.75 | $2.15M | -29.98% | |
| 2024-11-08 | Sale | MACARTNEY LAWSON | director | 2,000 0.0018% | $68.67 | $137,333 | -56.59% |
| FOEHR MATTHEW W | director | 132036 0.1035% | $3.44M | 5 | 2 | +1.62% |
| Aubuchon Neil William | Chief Commercial Officer | 4475 0.0035% | $116,752.75 | 1 | 0 | |
| MACARTNEY LAWSON | director | 47965 0.0376% | $1.25M | 1 | 4 | +92.12% |
| Rowland Charles A Jr | director | 30000 0.0235% | $782,700.00 | 1 | 2 | +92.12% |
| SINGLETON J MATTHEW | director | 9500 0.0074% | $247,855.00 | 1 | 5 | <0.0001% |
| Webster Stephen W | director | 8000 0.0063% | $208,720.00 | 1 | 0 | +92.12% |
| Rouan Sarah Kathryn | director | 1240 0.001% | $32,351.60 | 1 | 3 | +30.48% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$9,463,680 | 28 | 0.72% | $2.4B |
| Increased Positions | 235 | +53.41% | 13M | +17.24% |
| Decreased Positions | 187 | -42.5% | 14M | -19.05% |
| New Positions | 114 | New | 3M | New |
| Sold Out Positions | 47 | Sold Out | 5M | Sold Out |
| Total Postitions | 488 | +10.91% | 72M | -1.81% |
| Vanguard Group Inc | $354,168.00 | 8.85% | 10M | -163,525 | -1.61% | 2025-09-30 |
| Fmr Llc | $205,084.00 | 5.12% | 5.79M | -4M | -41.05% | 2025-09-30 |
| Blackrock, Inc. | $198,216.00 | 4.95% | 5.6M | +158,658 | +2.92% | 2025-09-30 |
| State Street Corp | $159,880.00 | 4% | 4.51M | +738,141 | +19.55% | 2025-09-30 |
| Morgan Stanley | $132,085.00 | 3.3% | 3.73M | +481,423 | +14.82% | 2025-09-30 |
| Jpmorgan Chase & Co | $91,280.00 | 2.28% | 2.58M | -61,968 | -2.35% | 2025-09-30 |
| Susquehanna International Group, Llp | $74,367.00 | 1.86% | 2.1M | +32,913 | +1.59% | 2025-09-30 |
| Ameriprise Financial Inc | $74,128.00 | 1.85% | 2.09M | +616,526 | +41.76% | 2025-09-30 |
| Two Sigma Investments, Lp | $73,868.00 | 1.85% | 2.09M | +771,704 | +58.74% | 2025-09-30 |
| Citadel Advisors Llc | $67,239.00 | 1.68% | 1.9M | +1M | +117.46% | 2025-09-30 |